Advanced Search

FOCUS, VOL. 4, No. 4

INFLUENTIAL PUBLICATIONS | September 01, 2006

Bibliography Psychopharmacology

FOCUS 2006;4:512-514.

Article

text A A A

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically. Articles from the bibliography that are reprinted in this issue are in bold type.

Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A: Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA2006; 295:2003—2017

Ballon JS, Feifel D: A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry2006; 67:554—566

Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV: Treatment of ADHD with stimulant medications: response to Nissen Perspective in [i]The New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry2006; 47:1147—1150

Chouinard G: The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci2006; 31:168—176

Claassen CA, Trivedi MH, Rush AJ, Husain MM, Zisook S, Young E, Leuchter A, Wisniewski SR, Balasubramani GK, Alpert J: Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. J Affect Disord 2006; Jul 7 (Epub ahead of print)

Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, Santin A, Kapczinski F: Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett2006; 398:215—219

Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C: Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry2006; 45:709—719

Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T: Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry2006; 59:P1052—P1060

Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH, STAR*D StudyTeam: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D Report. Am J Psychiatry2006; 163:1161—1172

Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry2006; 63:1079—1087

Lieberman JA: Comparative effectiveness of antipsychotic drugs. Arch Gen Psychiatry2006; 63:1069—1072

Lieberman JA, Hsiao JK: Interpreting the results of the CATIE study. Psychiatr Serv2006; 57:139

Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D, Wagner KD: ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology2006; 31:473—492

Mason BJ, Goodman AM, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res2006; 40:383—393

McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ, STAR*D Study Team: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry2006; 163:1531—1541

Menza M: STAR*D: the results begin to roll in. Am J Psychiatry2006163:1123

Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ, STAR*D Study Team: A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry2006; 163:1519—1530

Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry2006;163:217—224

Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Wisniewski SR, Trivedi MH, Talati A, Carlson MM, Liu HH, Fava M, Weissman MM: Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry2006; 67:126—136

Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology2006; 31:2514

Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry2006; 67(suppl 4):3—7

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry2006; 163:611—622

Thuerauf N, Lunkenheimer J: The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci2006; 256:287—293

Valenstein M: Keeping our eyes on STAR*D. Am J Psychiatry2006; 163:1484—1486

Alexopoulos GS, Katz IR, Bruce ML, Heo M, Ten Have T, Raue P, Bogner HR, Schulberg HC, Mulsant BH, Reynolds CF, PROSPECT Group: Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry2005; 162: 718—724

Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML, American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder: Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics2005; 115: e749—e757

Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Huton B: Between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. [bi]BMJ2005; 330: 396—399

Frank E, Novick D, Kupfer DJ: Antidepressants and psychotherapy: a clinical research review. Dialogues Clin Neurosci2005;7:263—272

Goldberg JF, Allen MH, Miklowitz DA, Bowden CL, Endick CJ, Chessick CA, Wisniewski SR, Miyahara S, Sagduyu K, Thase ME, Calabrese JR, Sachs GS: Suicidal ideation and pharmacotherapy among STEP-BD patients. Psychiatr Serv2005; 56:1534—1540

Gunnell D, Saperia J, Ashby D: Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ2005;330: 385—388

Insel TR: Beyond efficacy: the STAR*D trial. Am J Psychiatry2006; 163:5—7

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med2005; 353:1209—1223

Mason BJ: Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother2005; 6:2103—2115

National Institutes of Health: National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep2005; 28:1049—1057

Nemeroff CB: Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry2005;66(suppl 8):13—21

Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry2005; 162:1957—1960

Sharp J, Keefe B: Psychiatry in chronic pain: a review and update. Curr Psychiatry Rep2005; 7:213—219

Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients: Using antipsychotic agents in older patients. J Clin Psychiatry2004;65(suppl 2):5—99

Bouza C, Angeles M, Munoz A, Amate JM: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction2004; 99:811—828

Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry2004; 161:532—538

Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G: Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry2004; 161: 1864—1871

Marangell LB, Martinez JM, Ketter TA, Bowden CL, Goldberg JF, Calabrese JR, Miyahara S, Miklowitz DJ, Sachs GS, Thase ME, STEP-BD Investigators: Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disord2004; 6:139—143

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J, Treatment for Adolescents With Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA2004; 292:807—820

Mavissakalian MR: Switching from imipramine to sertraline in panic disorder. J Psychiatr Pract2004; 10: 88—94

Profenno LA, Tariot PN: Pharmacologic management of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord2004; 17:65—77

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH, STEP-BD Investigators: Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol2004; 24:512—520

Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP: Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry2004; 61:669—680

Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science2003; 301:386—389 (Reprinted in FOCUS, Winter 2005)

Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry2003; 60:553—564

Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry2003; 60:92—99

Leucht S, Barnes TRE, Kissling W, Engel R, Correll C, Kane J:Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and meta-analysis of randomised controlled trials. Am J Psychiatry2003; 160:1209—1222

Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet2003; 361:1581—1589

Littleton J, Zieglgansberger W: Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict2003; 12(suppl 1):S3—S11

Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus psychopharmacology in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA2003; 100:14293—14296 (Reprinted in FOCUS, Winter 2005)

Rothschild AJ, Duval SE: How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry2003; 64:390—396

Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF: Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry2003; 53: 1028—1042

Thase ME: Comparing the methods to use to compare antidepressants. Psychopharmacol Bull2002; 36(suppl 1)

Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA: Naltrexone in the treatment of alcohol dependence. N Engl J Med2001; 345:1734—1739

Harwood H: Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism. Rockville, MD, U.S. Department of Health and Human Services, 2000

Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P: Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry1997; 171:73—77

Sass H, Soyka M, Mann K, Zieglgansberger W: Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry1996; 53:673—680

Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P: Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol1995; 30:239—247

Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry1992;49:769—773

Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry1991; 148:997—1008 (Reprinted in FOCUS, Spring 2006)

Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry1990;47:1093—1099

References

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Bibliography Psychopharmacology' and do not need to have FOCUS: The Journal of Lifelong Learning in Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's FOCUS: The Journal of Lifelong Learning in Psychiatry: 'Bibliography Psychopharmacology'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

Bibliography Psychopharmacology. FOCUS: The Journal of Lifelong Learning in Psychiatry. 2006 Sep;4(4):512-514.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints